Read on Twitter
looking at $UROV Urovant's vibegron and it is hard not to compare alongside Synergy's plecanatide. (formely $SGYP, now $BHC)
-Both drugs are essentially me-toos, and are/were second to market in their class. Neither clearly differentiated from the competition.
-Both drugs were developed for relatively large indications and can be Rx'd by a GP or a specialist.
-Both drugs were developed for relatively large indications and can be Rx'd by a GP or a specialist.
-vibegron will compete w/ Myrbetriq (Astellas) in OAB: retails about $500/month and does about 800mm in sales US
-plecanatide competes w/ Linzess ($IRWD $AGN) in IBS-C: also retails about $500/month and does 800mm US
-plecanatide competes w/ Linzess ($IRWD $AGN) in IBS-C: also retails about $500/month and does 800mm US
Synergy couldn't sell plecanatide, the asset was acquired out of bankruptcy by Bausch in '19. This was partly d/t bad debt with crippling sales and liquidity covenants.
Urovant has a MUCH better capital structure thanks to major Sumitomo ownership.
Urovant has a MUCH better capital structure thanks to major Sumitomo ownership.
One thing plecanatide has going for it is the competition still has a decent patent life
Vibegron's competition drug goes off patent in 2023 AND it's a crowded market. Aside from Myrbetriq they compete w/ Toviaz, Vesicare, Enablix AND the old school oxybutynin and tolterodine.
Vibegron's competition drug goes off patent in 2023 AND it's a crowded market. Aside from Myrbetriq they compete w/ Toviaz, Vesicare, Enablix AND the old school oxybutynin and tolterodine.
